sing blood plasma to develop passive immunity to coronavirus in Ecuador

Phase 2

• Conditions: COVID-19 (SARS-CoV-2 infection); Respiratory

• Registration Number: ISRCTN85216856
• Lead Sponsor: niversidad Tecnológica Equinoccial

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-11
• Last Update Posted: 25 May 2020
• Study Completion: 2020-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Aged =18 years
2. Clinical, molecular (using IgM/IgG or RT-PCR), or lung imaging diagnosis of COVID-19
3. Deterioration of previously normal lung function defined as SaO2 of <90% in 0.5 FiO2, and/or a higher requirement of O2 than in the previous 24h
4. A score of 5 to 7 on the early warning scale for COVID-19 patients or a SOFA score between 2 and 10
5. Informed consent provided by patients or their representatives

Exclusion Criteria

1. Diagnosis and/or treatment for cancer
2. HIV infection
3. Currently receiving immunosuppressants for a condition other than SARS-CoV2 infection
4. Superimposed systemic infections
5. Liver or kidney failure
6. COPD, previous pulmonary fibrosis, and/or restrictive lung disease
7. Have received previous transfusions

Study & Design

• Study Type: Interventional
• Study Design: Not specified